Ibutamoren (MK-677): A Comprehensive Pharmacological and Clinical Monograph

Section 1: Compound Profile and Physicochemical Characteristics

Ibutamoren is an orally bioavailable, small molecule, non-peptide growth hormone secretagogue (GHS) that has been the subject of extensive investigation for its potential therapeutic applications.[1] As an investigational compound, it has been evaluated in numerous clinical trials, reaching a maximum phase of II for at least one indication.[1] This section provides a definitive chemical and physical profile of Ibutamoren, establishing the fundamental properties that govern its pharmacological behavior.

1.1. Nomenclature and Chemical Identifiers

To ensure unambiguous identification across chemical, pharmacological, and regulatory databases, Ibutamoren is cataloged under a variety of names and codes. The distinction between its free base and salt forms is critical for the accurate interpretation of scientific literature and experimental reproducibility.

• Generic Name: The International Nonproprietary Name (INN) for the compound is Ibutamoren. Variations include the Spanish ibutamoreno and the Latin ibutamorenum.[1]
• Developmental Codes: Throughout its history, Ibutamoren has been known by several developmental codes. It was originally developed by Merck & Co. under the codes MK-677, MK-0677, and L-163,191.[2] The L-163,191 designation represents a key milestone, signifying the successful optimization from a precursor compound (L-692,429) to achieve superior oral bioavailability and pharmacokinetic properties suitable for once-daily dosing.[5] More recently, its development for pediatric growth hormone deficiency has been advanced by Lumos Pharma under the code LUM-201.[2]
• Former Brand Name: A tentative brand name, Oratrope, was previously associated with the compound.[2]
• Registry Numbers: The most common identifiers are its DrugBank Accession Number, DB18214, and its Chemical Abstracts Service (CAS) Numbers. The CAS number for the free base is 159634-47-6. The mesylate salt form, which is frequently used in clinical studies and for research purposes due to its enhanced stability and solubility, is identified by CAS number 159752-10-0.[1]
• Other Identifiers: A comprehensive list of other identifiers facilitates cross-database referencing. These include the Unique Ingredient Identifier (UNII) GJ0EGN38UL, the ChEMBL ID CHEMBL13817, the PubChem Compound ID (CID) 9939050, and the IUPHAR/BPS ligand ID 5867.[1]

1.2. Molecular Structure and Computed Properties

Ibutamoren is classified as a small molecule drug, a designation supported by its molecular weight and non-peptide structure.[1] Its specific chemical arrangement and stereochemistry are essential for its high-affinity interaction with the ghrelin receptor.

• IUPAC Name: The systematic name for the compound is 2-amino-2-methyl-N--1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide.[1]
• Molecular Formula: The chemical formula for the free base is $C_{27}H_{36}N_{4}O_{5}S$.[1] The mesylate salt form has a molecular formula of $C_{28}H_{40}N_{4}O_{8}S_{2}$.[12]
• Molecular Weight: The average molecular weight of the free base is approximately 528.67 g/mol, with a monoisotopic mass of 528.24064144 Da.[1] The mesylate salt has a correspondingly higher average molecular weight of approximately 624.8 g/mol.[12]
• Structural Representations: Definitive structural information is provided by standardized chemical notations:
• InChI: InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1.[1]
• InChIKey: UMUPQWIGCOZEOY-JOCHJYFZSA-N.[1]
• SMILES (Isomeric): CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.[1]
• Physicochemical Properties: The computed properties of Ibutamoren are consistent with those of an orally bioavailable drug and predict its behavior in biological systems. It adheres to Lipinski's Rule of Five, indicating favorable "drug-likeness".[13] Key properties are summarized in Table 1. The relatively low value for logP (0.68) and significant polar surface area ($122.04 Å^2$) suggest a balance between lipid and aqueous solubility, which is essential for both absorption from the gastrointestinal tract and distribution in the bloodstream.[8]

1.3. Formulations and Stability

The physical characteristics of Ibutamoren dictate its handling, storage, and formulation for research and potential clinical use.

• Physical Appearance: In its solid state, Ibutamoren is typically a pale-yellow to yellow-brown powder.[11]
• Solubility: It demonstrates solubility in organic solvents such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and ethanol. It is noted that the hygroscopic nature of DMSO can significantly impact the solubility of the product, necessitating the use of freshly opened solvent for preparing stock solutions.[10]
• Storage and Stability: To ensure chemical integrity and prevent degradation, Ibutamoren should be stored in a dry, dark environment. Recommended short-term storage (days to weeks) is at 0-4°C, while long-term storage (months to years) requires colder temperatures of -20°C or -80°C. Stock solutions also have defined stability periods, typically one month at -20°C and up to six months at -80°C, with aliquoting recommended to avoid repeated freeze-thaw cycles.[4] The compound is considered stable enough for shipment under ambient temperatures as a non-hazardous chemical.[4]

Table 1: Chemical and Physicochemical Properties of Ibutamoren

Property	Value (Free Base)	Value (Mesylate Salt)	Source(s)
Generic Name	Ibutamoren	Ibutamoren Mesylate	2
Developmental Codes	MK-677, MK-0677, L-163,191, LUM-201	MK-0677	2
DrugBank ID	DB18214	-	8
CAS Number	159634-47-6	159752-10-0	1
UNII	GJ0EGN38UL	R90JB6QJ2B	1
IUPAC Name	2-amino-2-methyl-N--1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide	2-amino-2-methyl-N--1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid	1
Molecular Formula	$C_{27}H_{36}N_{4}O_{5}S$	$C_{28}H_{40}N_{4}O_{8}S_{2}$	1
Average Mol. Weight	528.67 g/mol	624.8 g/mol	8
Monoisotopic Mass	528.24064144 Da	624.22875659 Da	1
InChIKey	UMUPQWIGCOZEOY-JOCHJYFZSA-N	DUGMCDWNXXFHDE-VZYDHVRKSA-N	1
logP	0.68	-	8
pKa (Strongest Basic)	8.34	-	8
pKa (Strongest Acidic)	11.89	-	8
Polar Surface Area	122.04 $Å^2$	193 $Å^2$	8
H-Bond Acceptors	7	10	1
H-Bond Donors	2	3	8
Rotatable Bonds	7	8	8

Section 2: Molecular Pharmacology and Mechanism of Action

The pharmacological activity of Ibutamoren is defined by its specific and potent interaction with the ghrelin receptor. This interaction initiates a cascade of endocrine events that culminate in the amplified secretion of growth hormone and its downstream effectors. Understanding this mechanism is fundamental to interpreting its physiological effects, therapeutic potential, and safety profile.

2.1. The Ghrelin Receptor (GHSR): The Primary Target

Ibutamoren's effects are mediated through its action as a selective agonist at the Growth Hormone Secretagogue Receptor type 1a (GHSR1a), commonly known as the ghrelin receptor.[8] This receptor is a class A G protein-coupled receptor (GPCR) and serves as the endogenous target for ghrelin, a 28-amino acid peptide hormone primarily produced in the gut that is colloquially termed the "hunger hormone".[10]

The GHSR is predominantly coupled to G-alpha-q/11 proteins. Upon agonist binding, this coupling activates the phospholipase C (PLC) signaling pathway, which leads to the hydrolysis of phosphatidylinositol 4,5-bisphosphate ($PIP_2$) and the subsequent generation of the second messengers inositol trisphosphate ($IP_3$) and diacylglycerol (DAG).[8] This intracellular signaling cascade is the primary mechanism through which the receptor mediates its effects on hormone secretion.

A defining characteristic of the GHSR is its remarkably high level of constitutive, or agonist-independent, activity.[15] This means the receptor maintains a significant level of signaling even in the absence of a bound ligand. This basal activity is physiologically critical; mutations that result in a loss of GHSR constitutive activity have been directly associated with conditions such as familial short stature syndrome.[15] Therefore, Ibutamoren does not activate a dormant receptor but rather modulates a system that is already tonically active. This high baseline activity provides a rationale for the development of not only agonists like Ibutamoren but also inverse agonists designed to reduce signaling in states of receptor over-activity.[15]

2.2. Agonistic Action: Structural Basis of Binding and Receptor Activation

Ibutamoren is a potent, long-acting, orally active, non-peptide full agonist of the GHSR, designed to mimic the growth hormone-stimulating action of endogenous ghrelin.[2] Its binding affinity for the receptor is exceptionally high, with dissociation constant ($K_d$) values reported in the low nanomolar range (0.14-0.4 nM) and inhibitor constant ($K_i$) values as low as 0.24 nM.[8] Its functional potency is similarly high, with half-maximal effective concentration ($EC_{50}$) values for stimulating downstream signaling (e.g., calcium release) also in the low nanomolar range.[8]

High-resolution cryogenic electron microscopy (cryo-EM) studies have elucidated the structural basis for Ibutamoren's binding and subsequent activation of the GHSR.[15] These structural models reveal that Ibutamoren binds within a pocket formed by the transmembrane helices of the receptor. The activation mechanism involves key conformational changes in specific structural motifs. Notably, the rearrangement of an aromatic cluster of residues (W276, F279, H280, F312) and the modulation of a critical salt bridge (E124-R283) near the binding pocket are identified as essential for transitioning the receptor from its inactive to its active state.[15]

While Ibutamoren is a ghrelin mimetic, the precise nature of its agonism has been a subject of nuanced pharmacological investigation. Some literature has described growth hormone secretagogues as "ago-allosteric" ligands, implying they may bind to a distinct site or in a manner that also modulates the receptor's response to ghrelin itself.[17] However, a more detailed functional analysis, supported by early mutational studies suggesting an overlapping binding site with ghrelin, posits that these compounds are better described as orthosteric super-agonists.[18] This model suggests that Ibutamoren binds to the same site as ghrelin but possesses a higher intrinsic efficacy, meaning it is a more effective activator of the receptor than the body's own endogenous ligand. This "super-agonist" property could account for its potent physiological effects. It may also, however, have implications for long-term receptor regulation, potentially leading to desensitization, a phenomenon that has been observed in animal models where the GH response to Ibutamoren was abolished after six weeks of continuous treatment.[19]

2.3. Downstream Signaling and Endocrine Cascade: The GH/IGF-1 Axis

The primary physiological consequence of GHSR activation by Ibutamoren is the potent stimulation of the growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis.[1] By acting on GHSRs located on somatotroph cells in the anterior pituitary gland, Ibutamoren promotes the pulsatile release of growth hormone (GH) into circulation.[1] This action results in a significant and sustained increase in plasma GH levels.[1]

The elevated circulating GH then acts on its primary target organ, the liver, to stimulate the synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1).[2] The result is a durable increase in plasma IGF-1 concentrations, which mediate many of the anabolic and metabolic effects of growth hormone. Clinical studies have demonstrated the potency of this effect; a daily 25 mg oral dose of Ibutamoren was shown to increase the mean 24-hour GH concentration by up to 97% and significantly elevate IGF-1 levels.[22]

A critical distinction between Ibutamoren and therapy with exogenous recombinant human growth hormone (rHGH) is the nature of the GH increase. Ibutamoren stimulates the body's endogenous secretory machinery, preserving the natural, pulsatile pattern of GH release.[5] This is in contrast to the sustained, non-pulsatile elevation of GH levels seen with direct rHGH injections. Because it works through the physiological pathway, Ibutamoren's action is subject to the body's natural negative feedback mechanisms and does not suppress the pituitary's intrinsic ability to produce GH.[5]

While its primary effect is on the GH/IGF-1 axis, Ibutamoren administration has also been associated with transient increases in other hormones, including cortisol and prolactin.[2] However, this effect appears to attenuate with chronic dosing, and some studies report no significant impact on cortisol levels, particularly with long-term treatment.[4]

Section 3: Pharmacokinetics and Human Metabolism (ADME)

The clinical utility and dosing strategy for any therapeutic agent are dictated by its pharmacokinetic profile—its absorption, distribution, metabolism, and excretion (ADME). Ibutamoren was specifically designed to possess favorable pharmacokinetics for oral administration, a key advantage over earlier peptide-based secretagogues.

3.1. Absorption, Bioavailability, and Half-Life

Ibutamoren is characterized by its excellent oral activity, a primary objective during its development by Merck.[1] This allows for convenient administration as a tablet or capsule, obviating the need for the injections required by most peptide-based GHSs.[21]

• Oral Bioavailability: The oral bioavailability of Ibutamoren in humans is high, reported to be greater than 60%.[5] This efficient absorption from the gastrointestinal tract is a hallmark of the compound and central to its potential as a therapeutic agent.
• Elimination Half-Life: The plasma elimination half-life of the parent Ibutamoren molecule is approximately 4 to 6 hours.[2]
• Duration of Action: A notable feature of Ibutamoren is the marked disconnect between its pharmacokinetic half-life and its pharmacodynamic duration of action. While the parent drug is cleared from the plasma relatively quickly, a single oral dose is sufficient to produce a sustained elevation of IGF-1 levels that persists for up to 24 hours.[2] This prolonged biological effect is not due to the persistence of Ibutamoren itself, but rather to the downstream physiological cascade it initiates. The initial pulsatile release of GH stimulated by Ibutamoren leads to hepatic production of IGF-1. IGF-1 has a much longer circulating half-life than both GH and Ibutamoren, thereby extending the ultimate biological effect of a single dose.[5] This pharmacokinetic/pharmacodynamic profile is what makes a once-daily dosing regimen clinically feasible and effective.[6]

3.2. Metabolic Pathways and Key Metabolites

Understanding the metabolic fate of Ibutamoren is essential for characterizing its complete pharmacological activity and for developing methods for its detection in doping control. Human metabolism studies following a single 10 mg oral dose have identified a two-phase metabolic process.[26]

• Phase I Metabolism: The primary Phase I metabolic pathways involve oxidative modifications and structural cleavage. Key transformations include:
• Hydroxylation: Mono-, di-, and even tri-hydroxylation of the parent molecule are significant pathways.[26]
• Side-Chain Cleavage: The molecule can be cleaved, resulting in the loss of the benzyl fragment or the 2-amino-2-methylpropanamide group.[26]
• Phase II Metabolism: The hydroxylated metabolites generated during Phase I can undergo subsequent conjugation. The principal Phase II pathway observed is glucuronidation, where glucuronic acid is attached to the hydroxyl groups. Notably, no sulfated conjugates have been detected in human urine samples.[26]

The kinetics of metabolite appearance in urine follow a predictable pattern. The highest concentration of the unchanged parent drug is observed approximately 1.7 hours after ingestion. In contrast, the peak concentration of the major hydroxylated metabolite appears later, at around 5.5 hours post-dose, reflecting the time required for metabolic conversion.[26]

3.3. Excretion and Detection for Doping Control

The excretion profile of Ibutamoren and its metabolites is of paramount importance to anti-doping organizations. The ability to detect these compounds in urine long after administration is the basis for its prohibition in competitive sports.

• Detection Window: The detection window for Ibutamoren is substantial due to the persistence of its metabolites.
• The unchanged parent compound can be detected in urine for up to 70 hours (nearly 3 days) following a single oral dose.[26]
• The metabolites, particularly the hydroxylated forms, offer a longer window of detection. The primary hydroxylated metabolite can be identified in urine for up to 94 hours (approximately 4 days) post-administration, making it a robust target for anti-doping screening.[26] Studies in thoroughbred horses have shown similar results, with major metabolites detectable for up to 96 hours.[27]

This extended detection window makes it a high-risk substance for athletes attempting to evade detection and provides a strong scientific rationale for its inclusion on the World Anti-Doping Agency's Prohibited List.

Section 4: Clinical Development and Efficacy Assessment

The clinical development of Ibutamoren has been a long and complex journey, marked by initial promise across a range of indications, followed by significant setbacks and a more recent refocusing on a niche therapeutic area. This section provides a systematic review of the clinical evidence, evaluating its efficacy in various patient populations and for different therapeutic goals.

Table 2: Summary of Key Clinical Trials for Ibutamoren (MK-677)

Indication	Study Population	Duration	Dosage	Key Outcomes (Primary Endpoint)	Result Summary	Source(s)
Diet-Induced Catabolism	8 healthy male volunteers	7 days (treatment phase)	25 mg/day	Nitrogen Balance	Reversed negative nitrogen balance, increased GH and IGF-1.	25
Frailty (Older Adults)	65 healthy adults (60-81 yrs)	2 years	25 mg/day	Fat-Free Mass (FFM), Abdominal Visceral Fat (AVF)	Significantly increased FFM; no change in AVF. Did not improve strength or function.	23
Obesity (Males)	24 obese males (19-49 yrs)	8 weeks	25 mg/day	GH secretion, Body Composition	Increased GH, IGF-1, and FFM. No significant change in total or visceral fat.	24
Pediatric GHD	68 prepubertal children	Single dose & 6 months	0.8 mg/kg	Peak GH response, Height Velocity	Elicited greater GH response than standard stimuli. Modestly increased height velocity.	7
Postmenopausal Osteoporosis	292 women (64-85 yrs)	18 months	25 mg/day (± Alendronate)	Bone Mineral Density (BMD)	Increased femoral neck BMD vs. alendronate alone. No benefit at other sites.	32
Alzheimer's Disease	563 patients (mild-mod AD)	12 months	25 mg/day	CIBIC-plus, ADAS-Cog	No efficacy. Failed to slow cognitive or functional decline despite increasing IGF-1.	34
Fibromyalgia	64 female patients	24 weeks	25 mg/day	Fibromyalgia Impact Questionnaire (FIQ)	Phase 2 trial completed (NCT00116129); results not publicly available in provided data.	3

4.1. Developmental History

Ibutamoren was discovered and developed by Merck Research Laboratories in the mid-1990s under the internal designation MK-677.[21] The primary goal was to create a potent, non-peptide, orally active growth hormone secretagogue that could overcome the significant limitations of earlier peptide-based compounds, such as GHRP-6, which suffered from poor oral bioavailability and short half-lives.[6]

Early clinical studies published in the late 1990s demonstrated considerable promise. Merck-led trials confirmed that MK-677 could potently and durably stimulate the GH/IGF-1 axis in various populations, including healthy elderly subjects, adults with growth hormone deficiency, and obese males, effectively restoring hormone levels to those seen in young adults.[2] These findings spurred further investigation into its potential as a treatment for age-related frailty, catabolic states, and osteoporosis.

However, the compound's development encountered major obstacles. A large clinical trial investigating its use to improve outcomes in elderly patients recovering from hip fracture was terminated prematurely. This decision was driven by a safety signal indicating a potential increased risk of congestive heart failure among patients receiving the drug, a significant adverse event that raised serious concerns about its cardiovascular safety profile.[38]

Another major setback came from a large-scale, 12-month, multicenter study involving 563 patients with mild-to-moderate Alzheimer's disease.[34] The trial was predicated on preclinical evidence that IGF-1 could help clear β-amyloid from the central nervous system. While the study successfully demonstrated target engagement—Ibutamoren administration led to a robust and sustained increase in serum IGF-1 levels of over 70%—it completely failed to meet its primary efficacy endpoints. There was no significant difference between the Ibutamoren and placebo groups in the rate of cognitive or functional decline.[34] This outcome served as a cautionary tale regarding therapeutic strategies based solely on manipulating surrogate biomarkers without a complete understanding of the disease pathophysiology.

Following these setbacks, the development of Ibutamoren for broad indications like frailty and neurodegenerative disease stalled. More recently, the compound has been repurposed by Lumos Pharma under the new code LUM-201. The developmental focus has shifted to a more specific and targeted indication: pediatric growth hormone deficiency (PGHD), where the benefit of an oral therapy could provide a significant advantage over existing treatments.[2]

4.2. Indication: Growth Hormone Deficiency (GHD)

The treatment of growth hormone deficiency represents the most active and promising area of current clinical development for Ibutamoren. Its potential as an oral alternative to daily injections of recombinant human growth hormone (rHGH) addresses a significant unmet need, particularly in the pediatric population.

Pediatric Growth Hormone Deficiency (PGHD):

Ibutamoren, as LUM-201, is being evaluated in Phase 2 clinical trials for PGHD.7 The OraGrowtH212 trial has shown that once-daily oral administration can restore endogenous GH secretion patterns and serum IGF-1 concentrations to levels that approximate those of healthy children.39

A key finding from a study of 68 prepubertal children with GHD was Ibutamoren's superior potency in stimulating GH release compared to standard diagnostic agents. A single oral dose of Ibutamoren (0.8 mg/kg) elicited a median peak GH response of 15.0 ng/mL, significantly higher than the 5.5 ng/mL median peak achieved with conventional stimuli like arginine, clonidine, or glucagon ($p < 0.0001$).[7]

However, the therapeutic response to Ibutamoren is not uniform across all GHD patients. Further analysis has revealed that a patient's baseline IGF-1 level and their peak GH response to an initial test dose of Ibutamoren are predictive enrichment markers (PEMs) for treatment success.[7] Children who are "PEM-positive" (i.e., have higher baseline IGF-1 and a robust GH response to the drug) tend to exhibit a better growth response, measured by annualized height velocity, when treated with Ibutamoren. This suggests that Ibutamoren may be most effective in a specific subset of GHD patients who retain a functional pituitary-hypothalamic axis capable of responding to the stimulus. This patient stratification approach is a key element of its current development strategy, aiming to identify the population most likely to benefit from this oral therapy. In earlier studies, the increase in height velocity with Ibutamoren was modest compared to placebo and less pronounced than that typically achieved with standard injectable rHGH therapy, reinforcing the need for careful patient selection.[31]

Adult Growth Hormone Deficiency (GHD):

Early research in a small cohort of nine young adults with childhood-onset GHD demonstrated that oral MK-677 could effectively increase 24-hour mean GH and serum IGF-1 concentrations.37 An important observation from this study was that the magnitude of the hormonal response was positively correlated with the patient's baseline GH and IGF-1 levels. This indicates that individuals with less severe deficiency, and thus a more responsive pituitary, derive the greatest benefit from the drug.37

4.3. Indication: Body Composition (Frailty, Sarcopenia, Obesity)

A primary focus of early Ibutamoren research was its potential to counteract age-related sarcopenia and frailty by leveraging its potent anabolic effects. Clinical trials have consistently shown that Ibutamoren can increase lean body mass, but the translation of this effect into functional improvement has been a significant challenge.

Frailty in the Elderly:

A landmark two-year, randomized, placebo-controlled trial in 65 healthy older adults (ages 60-81) investigated the long-term effects of 25 mg/day of MK-677.23 The treatment successfully restored GH and IGF-1 levels to those characteristic of healthy young adults.23 This hormonal shift produced a significant effect on body composition: over 12 months, subjects in the MK-677 group gained an average of 1.1 kg of fat-free mass (FFM), while the placebo group lost 0.5 kg. Body weight also increased significantly more in the treatment group (2.7 kg vs. 0.8 kg).23 Despite these robust anabolic effects on muscle mass, the study found that the increase in FFM did not translate into any measurable improvements in muscle strength or physical function.23 This efficacy-function mismatch is a critical finding, as it questions whether the lean mass accrued is functional contractile tissue and whether increasing muscle mass alone is sufficient to combat frailty.

Obesity:

In a two-month study of healthy obese males, MK-677 treatment also led to a significant increase in FFM.24 The treatment was associated with a transient increase in basal metabolic rate at two weeks, though this effect was not sustained at eight weeks. However, despite the anabolic effects, there was no significant change in total body fat or visceral fat mass.24 This contrasts with data from a study in hypogonadal men, where Ibutamoren use was associated with a significant 9.7% decrease in body fat mass alongside a 9.7% increase in lean body mass.44 The discrepancy suggests that the drug's effect on adiposity may be context-dependent, possibly influenced by the subject's underlying hormonal status, such as testosterone levels.

Catabolic States:

Ibutamoren has demonstrated efficacy in reversing protein catabolism. In a crossover study, healthy volunteers were placed on a calorie-restricted diet to induce a state of negative nitrogen balance. Subsequent treatment with 25 mg/day of MK-677 for seven days successfully reversed this catabolic state, shifting the subjects from a mean daily nitrogen balance of -1.48 g/day (on placebo) to a positive balance of +0.31 g/day.25 This finding suggests potential utility in treating conditions characterized by muscle wasting.

4.4. Indication: Bone Health (Osteoporosis)

Given that growth hormone plays a role in bone remodeling, Ibutamoren has been investigated as a potential therapy for osteoporosis, both as a monotherapy and in combination with anti-resorptive agents.

Studies in obese young males found that two months of treatment with MK-677 increased biochemical markers of both bone formation (e.g., osteocalcin) and bone resorption (e.g., urinary N-telopeptide cross-links, CTX), indicating an overall increase in the rate of bone turnover.[45]

A large, 18-month clinical trial in 292 postmenopausal women with osteoporosis provided more definitive data on its effects on bone mineral density (BMD).[32] The study evaluated MK-677 (25 mg/day) alone and in combination with the bisphosphonate alendronate. The results showed a complex and site-specific effect. The combination of MK-677 and alendronate resulted in a significantly greater increase in BMD at the femoral neck compared to alendronate alone (4.2% vs. 2.5% increase, $p < 0.05$). This suggests a synergistic or additive anabolic effect at this critical fracture site. However, this benefit was not observed at other skeletal sites. There was no significant additional increase in BMD at the lumbar spine, total hip, or in the total body when MK-677 was added to alendronate.[32] The data suggest that while Ibutamoren stimulates bone remodeling, its net effect on bone mass is modest and may not be sufficient to warrant its use as a primary treatment for osteoporosis, especially given its side effect profile.

4.5. Ancillary Therapeutic Targets: Fibromyalgia and Sleep

Beyond its primary effects on growth and body composition, Ibutamoren has been explored for other conditions, notably fibromyalgia and sleep disorders.

Fibromyalgia:

A Phase 2 clinical trial (NCT00116129) was completed to evaluate the efficacy and safety of Ibutamoren for the treatment of fibromyalgia syndrome.3 The rationale was based on observations that many fibromyalgia patients exhibit signs of relative growth hormone deficiency. The 24-week, randomized, double-blind, placebo-controlled study enrolled 64 female subjects and used the Fibromyalgia Impact Questionnaire (FIQ) as its primary endpoint.35 Despite the trial's completion, its results have not been made widely available in the public domain, creating a significant gap in the understanding of Ibutamoren's potential in this indication.35

Sleep Architecture:

One of the most robust and consistently demonstrated effects of Ibutamoren is its ability to improve sleep quality.2 This effect is likely linked to the close physiological relationship between slow-wave sleep and the nocturnal peak of GH secretion. Clinical studies in both young and older adults have shown significant improvements in sleep architecture with bedtime administration of the drug.50 In young, healthy subjects, a 25 mg dose of MK-677 increased the duration of Stage IV (deep, slow-wave) sleep by approximately 50% and increased REM sleep duration by over 20% compared to placebo. In older adults, who typically experience a decline in sleep quality, treatment was associated with a nearly 50% increase in REM sleep and a reduction in REM latency.50 This potent effect on sleep could be a valuable therapeutic benefit, either as a primary treatment for sleep disorders or as an important secondary benefit in conditions where sleep is commonly disrupted, such as frailty or fibromyalgia.

Section 5: Comprehensive Safety and Tolerability Profile

A thorough assessment of an investigational drug's safety profile is paramount to understanding its potential risk-benefit ratio. While Ibutamoren has shown efficacy in modulating the GH/IGF-1 axis, its clinical development has been significantly constrained by a range of adverse events, from common, mild side effects to serious safety concerns that have halted major trials.

5.1. Common and Transient Adverse Events

Across numerous clinical trials, a consistent pattern of common, generally mild-to-moderate adverse events has been reported. These effects are largely predictable based on the drug's mechanism of action as a ghrelin mimetic and a potent stimulator of growth hormone.

• Increased Appetite: As a direct consequence of agonizing the ghrelin receptor, a significant increase in appetite is one of the most frequently reported side effects.[21] While this can be a therapeutic benefit in patients with cachexia or muscle wasting, it is often an undesirable effect in other populations. Some long-term studies note that this effect tends to subside within a few months of continuous treatment, suggesting a degree of receptor adaptation or behavioral adjustment.[23]
• Fluid Retention (Edema): Transient, mild lower extremity edema is another common finding.[20] This is a well-known side effect of elevated growth hormone levels, which can alter renal sodium and water handling.
• Musculoskeletal Pain: Mild muscle pain (myalgia) and joint pain (arthralgia) are frequently reported, particularly in the initial phases of treatment.[5]
• Other Effects: Other commonly reported but less frequent side effects include transient anxiety, numbness or paresthesias, fatigue or lethargy, and an increase in vivid dreams, the last of which is likely related to its effects on REM sleep.[20]

5.2. Metabolic Consequences

The most significant and consistent safety concern associated with Ibutamoren use is its adverse impact on glucose metabolism. This effect stems directly from the physiological actions of growth hormone, which is a counter-regulatory hormone to insulin.

• Hyperglycemia and Insulin Resistance: Numerous studies have demonstrated that Ibutamoren treatment leads to a measurable increase in fasting blood glucose levels and a corresponding decrease in insulin sensitivity.[21] In a study of older adults, fasting glucose increased by an average of 5 mg/dL.[23] An oral glucose tolerance test in obese males showed impairment of glucose homeostasis after just two weeks of treatment.[24] This consistent finding raises significant concerns that long-term use of Ibutamoren could unmask latent diabetes or increase the risk of developing type 2 diabetes, particularly in predisposed individuals.[54]
• Lipid Profiles: The effect of Ibutamoren on blood lipids is less clear and may be contradictory. A long-term study in older adults reported a beneficial decrease in LDL cholesterol.[5] In contrast, a case report involving the co-administration of Ibutamoren with a Selective Androgen Receptor Modulator (SARM) noted a deleterious effect on the lipid profile, including increased total cholesterol and LDL, and a sharp decrease in HDL.[56] This suggests the impact on lipids may be influenced by other factors or co-administered substances.
• Cortisol Levels: While some studies have noted a transient increase in cortisol secretion immediately following dosing, this effect does not appear to be sustained with chronic administration, and long-term studies have generally found no significant increase in mean serum or urinary cortisol concentrations.[5]

The adverse metabolic profile, particularly the diabetogenic potential, represents a fundamental challenge for the drug. The desired anabolic effects of increased GH/IGF-1 are intrinsically linked to the undesired metabolic consequences. This trade-off is not an incidental side effect but a core feature of the drug's mechanism, making patient selection and careful metabolic monitoring essential for any potential therapeutic use.

5.3. Serious Adverse Events and Long-Term Safety Concerns

Beyond the common and metabolic side effects, the clinical development of Ibutamoren has been impacted by several serious adverse events and long-term safety concerns that have limited its therapeutic potential.

• Cardiovascular Risk: The most significant safety signal to date arose from a clinical trial in elderly patients with hip fracture, which was terminated early due to an observed increase in the incidence of congestive heart failure in the treatment group.[38] This finding led the U.S. Food and Drug Administration (FDA) to specifically list Ibutamoren as an ingredient that "poses significant safety risks due to the potential for congestive heart failure in certain patients".[38] This remains a major barrier to its use, especially in older, more vulnerable populations.
• Hepatotoxicity: While not a common finding in controlled trials, there is at least one published case report of drug-induced liver injury associated with Ibutamoren use. An otherwise healthy male in his 30s developed elevated liver enzymes (transaminitis) after consuming MK-677 for two months; liver function returned to normal upon discontinuation of the supplement.[57] This suggests a potential for idiosyncratic hepatotoxicity.
• Oncological Risk: A major theoretical concern for any therapy that chronically elevates levels of potent growth factors like GH and IGF-1 is the potential risk of promoting the growth of pre-existing or new malignancies.[20] IGF-1 is a powerful mitogen that stimulates cell proliferation and inhibits apoptosis. While no definitive link has been established in Ibutamoren trials, this long-term risk remains a significant consideration and a likely reason for regulatory caution regarding its chronic use.
• Bone Health: The data on bone health is contradictory. While some clinical trials have investigated Ibutamoren as a potential treatment to increase bone density [32], other health advisories warn that it can decrease bone mineral density.[21] This discrepancy may relate to its effect of increasing overall bone turnover; in some contexts, if resorption outpaces formation, a net loss of bone mass could occur.

Section 6: Regulatory Landscape and Illicit Use

The regulatory status of Ibutamoren is characterized by a stark dichotomy: on one hand, it is a legitimate investigational drug pursuing a narrow, formal approval pathway for a rare disease; on the other, it is a widely abused substance sold illicitly on a global grey market. This dual identity creates significant public confusion and poses a major challenge for regulatory and anti-doping agencies.

6.1. Global Regulatory Status

Officially, Ibutamoren is an unapproved, experimental drug worldwide. It has not been approved for marketing or human consumption for any indication in any major jurisdiction.

• United States (FDA): In the U.S., Ibutamoren holds the status of an Investigational New Drug (IND).[2] In recognition of its potential to treat a rare condition, the FDA granted it Orphan Drug Designation in June 2017 for the treatment of growth hormone deficiency.[58] This designation provides incentives for its clinical development but does not imply safety, efficacy, or approval. The FDA actively polices the illicit market, frequently issuing warning letters to companies illegally selling Ibutamoren, particularly those marketing it as a dietary supplement or "research chemical" for human use.[38]
• European Union (EMA): Similar to the U.S., the European Commission granted orphan designation to Ibutamoren mesilate in June 2017 for the treatment of growth hormone deficiency.[58]
• Australia (TGA): The Therapeutic Goods Administration (TGA) of Australia has taken a clear regulatory stance. Ibutamoren is classified as a Schedule 4 (Prescription Only Medicine) substance. Furthermore, it is included in Appendix D, which lists substances with a high potential for misuse or abuse.[38] It is not an active ingredient in any medicine registered on the Australian Register of Therapeutic Goods (ARTG).[58]

6.2. Prohibition in Sport: The World Anti-Doping Agency (WADA)

Due to its potent effects on the GH/IGF-1 axis and its clear potential for performance enhancement, Ibutamoren is unequivocally banned in competitive sports.

• WADA Prohibited List: Ibutamoren is explicitly named and prohibited at all times (both in- and out-of-competition) for all athletes subject to the World Anti-Doping Code. It is listed under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.[38] Its classification as a growth hormone secretagogue automatically places it within this prohibited category.[62]

6.3. The Grey Market: Unapproved Sales and Public Health Risks

Despite its unapproved status and known safety risks, Ibutamoren is widely available for purchase online and through unauthorized vendors. This "grey market" poses a significant public health risk.

• Illicit Marketing and Sales: Ibutamoren is frequently and deceptively marketed to the public, particularly within the bodybuilding and anti-aging communities.[2] It is often sold under the guise of a "research chemical not for human consumption" to circumvent regulations, yet it is accompanied by claims of muscle growth, fat loss, and recovery.[4] It is also commonly mislabeled or sold alongside Selective Androgen Receptor Modulators (SARMs), despite being mechanistically distinct.[38]
• Product Quality and Safety: Products sold on this unregulated market come with no guarantees of quality, purity, or accurate dosage. A 2017 study published in JAMA that analyzed products marketed as SARMs found that a significant portion were mislabeled, contained unlisted ingredients, or had dosages that differed from the label.[4] Consumers of grey market Ibutamoren face similar risks of consuming contaminated or incorrectly dosed products, in addition to the inherent risks of the drug itself.

This regulatory dichotomy, where a slow, cautious, and legitimate development pathway for a rare disease runs parallel to an explosive and uncontrolled illicit market, creates a confusing and dangerous environment for the public. The adverse events that inevitably occur in the unregulated user population could potentially jeopardize the legitimate clinical development of a drug that may hold real promise for a small, well-defined patient group.

Section 7: Comparative Analysis and Future Perspectives

To fully contextualize Ibutamoren's potential role in medicine, it is essential to compare it against alternative therapies that target the growth hormone axis. This analysis highlights its unique advantages, such as oral administration, as well as its significant limitations in efficacy and safety compared to established and other investigational agents.

7.1. Ibutamoren vs. Injectable Peptide GHSs

Ibutamoren belongs to a class of drugs known as growth hormone secretagogues, but it is distinct from many others in this class which are peptide-based. Key comparators include Sermorelin, CJC-1295, and Ipamorelin.

• Administration: The most significant advantage of Ibutamoren is its oral route of administration. In contrast, peptide-based GHSs like Sermorelin, CJC-1295, and Ipamorelin are not orally bioavailable and must be administered via subcutaneous injection, which is less convenient and can be a barrier to patient adherence.[20]
• Mechanism and Side Effect Profile: The mechanistic differences lead to distinct side effect profiles. Ibutamoren is a ghrelin receptor agonist, and its potent stimulation of this receptor leads to a marked increase in appetite.[20] While this can be useful in wasting states, it is often an undesirable side effect. In contrast, peptides like Ipamorelin stimulate GH release with high specificity and little to no effect on appetite or other hormones like cortisol and prolactin. This makes Ipamorelin a more "targeted" GHS, often preferred for applications where weight gain or metabolic disruption are concerns.[20]
• Efficacy and Duration: Different GHSs have varying pharmacokinetic profiles. For instance, CJC-1295 is known for providing a more sustained release and elevation of GH levels compared to the more acute pulse generated by other peptides. Ibutamoren, while having a short half-life itself, produces a long-lasting effect on IGF-1.[2] The choice between agents often depends on the desired therapeutic goal, whether it be mimicking a natural pulse or achieving a more sustained elevation of the GH/IGF-1 axis.

7.2. Ibutamoren vs. Recombinant Human Growth Hormone (rHGH)

The most critical comparison is between Ibutamoren, which stimulates endogenous GH production, and recombinant HGH (rHGH), which involves the direct replacement of the hormone. This comparison highlights the fundamental differences in their approach to treating GH-related conditions.

• Mechanism of Action: Ibutamoren works by stimulating the pituitary gland to release its own GH in a physiological, pulsatile manner. This process remains subject to the body's natural negative feedback loops, which theoretically reduces the risk of excessive hormone levels.[5] In contrast, rHGH is the direct administration of synthetic GH, which results in sustained, non-pulsatile, and often supraphysiological hormone levels. Chronic rHGH use can suppress the pituitary's natural ability to produce GH, potentially leading to dependency.[22]
• Efficacy: Both therapies are effective at increasing circulating GH and IGF-1 levels, which translates to increases in lean body mass and, in some cases, decreases in fat mass.[22] However, in direct comparisons for pediatric growth, rHGH has been shown to produce a greater increase in height velocity than Ibutamoren, suggesting it is a more potent growth-promoting agent.[31]
• Safety and Side Effects: While the pulsatile release from Ibutamoren is theoretically safer, the clinical data show that it causes many of the same side effects associated with rHGH therapy. These include edema, joint and muscle pain, and, most importantly, insulin resistance and hyperglycemia.[5] The risk of congestive heart failure observed in one Ibutamoren trial is also a significant concern.[38] Therefore, Ibutamoren has not yet demonstrated a decisively superior clinical safety profile over rHGH.
• Regulatory Status: rHGH is an approved, albeit tightly regulated, prescription medication for specific indications like documented GHD. Its off-label use for anti-aging or performance enhancement is illegal in many countries.[22] Ibutamoren remains an unapproved, investigational drug for all uses, though it is widely available on the grey market.[2]

Table 3: Comparative Profile: Ibutamoren vs. Recombinant HGH

Feature	Ibutamoren (MK-677)	Recombinant HGH (rHGH)
Administration Route	Oral (tablet/capsule)	Subcutaneous Injection
Mechanism of Action	Stimulates endogenous GH secretion (GHSR agonist)	Exogenous replacement with synthetic GH
Effect on Endogenous GH	Does not suppress; enhances natural production	Suppresses natural pituitary production
Nature of GH Increase	Pulsatile, mimics physiological rhythm	Sustained, non-pulsatile, often supraphysiological
Key Efficacy Points	Increases FFM, IGF-1, and bone turnover. Modest effect on height velocity in GHD.	Increases FFM, IGF-1, and bone density. Potent effect on height velocity in GHD.
Key Side Effects	Increased appetite, edema, muscle/joint pain, insulin resistance, increased blood glucose.	Edema, muscle/joint pain, carpal tunnel syndrome, insulin resistance, increased blood glucose.
Regulatory Status	Investigational New Drug; Unapproved. Orphan Drug Designation for GHD.	Approved prescription drug for specific indications; highly regulated.
Doping Status (WADA)	Prohibited at all times (Class S2)	Prohibited at all times (Class S2)

7.3. Synthesis and Future Outlook

Ibutamoren (MK-677) is a pharmacologically potent, orally active growth hormone secretagogue that reliably stimulates the GH/IGF-1 axis. Its clinical profile is defined by consistent anabolic effects on lean body mass and a unique, robust ability to improve the quality of deep and REM sleep. These properties initially suggested broad therapeutic potential in conditions ranging from age-related frailty to osteoporosis.

However, its journey through clinical development has been largely unsuccessful. The failure to translate increased muscle mass into improved physical function in the elderly has questioned its clinical relevance for sarcopenia. Furthermore, its development has been critically hampered by a challenging safety profile, most notably its adverse metabolic effects on glucose homeostasis and a serious cardiovascular safety signal that halted a major trial. Consequently, its potential for widespread use in chronic conditions affecting large populations appears limited.

The future of Ibutamoren in legitimate medicine is likely confined to a narrow, well-defined therapeutic niche. Its current development for pediatric growth hormone deficiency is the most viable path forward. In this context, its oral route of administration offers a profound quality-of-life advantage over the burden of daily injections for children. The strategy of using predictive biomarkers to select a sub-population of patients most likely to respond represents a sophisticated, personalized medicine approach that may maximize its benefit-risk ratio. For Ibutamoren to succeed, even in this niche, long-term studies will be required to definitively establish its safety, particularly concerning metabolic health, and to overcome the potential for receptor desensitization observed in preclinical models.

Outside of this formal pathway, Ibutamoren will almost certainly persist as a substance of abuse in athletic and bodybuilding circles, where its potent anabolic effects are sought despite the known risks. This ongoing illicit use will continue to pose a challenge for public health and anti-doping authorities. Ultimately, Ibutamoren serves as a compelling case study in drug development: a compound with a potent and desirable mechanism of action whose broad clinical utility is constrained by the inseparable and inherent physiological trade-offs of the system it modulates.

Works cited

1. Ibutamoren | C27H36N4O5S | CID 178024 - PubChem, accessed October 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ibutamoren
2. Ibutamoren - Wikipedia, accessed October 22, 2025, https://en.wikipedia.org/wiki/Ibutamoren
3. Fibromyalgia Syndrome Completed Phase 2 Trials for Ibutamoren ..., accessed October 22, 2025, https://go.drugbank.com/indications/DBCOND0033306/clinical_trials/DB18214?phase=2&status=completed
4. Ibutamoren | CAS#159634-47-6 | growth hormone secretagogue - MedKoo Biosciences, accessed October 22, 2025, https://www.medkoo.com/products/20415
5. The Safety and Efficacy of Growth Hormone Secretagogues - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
6. Ibutamoren mesylate - The University of Maryland, Baltimore, accessed October 22, 2025, https://archive.hshsl.umaryland.edu/bitstreams/5c021704-039d-4463-a4a8-256633f96fbd/download
7. A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH ..., accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9227666/
8. Ibutamoren: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/drugs/DB18214
9. Ibutamoren - CAS - 159634-47-6 - Axios Research, accessed October 22, 2025, https://axios-research.com/ibutamoren
10. Ibutamoren (mesylate) (CAS 159752-10-0) - Cayman Chemical, accessed October 22, 2025, https://www.caymanchem.com/product/18003/ibutamoren-mesylate
11. IBUTAMOREN (MK-677) | 159634-47-6 - Sigma-Aldrich, accessed October 22, 2025, https://www.sigmaaldrich.com/US/en/product/astatechinc/ateh97e303b2?context=bbe
12. MK 0677 | C28H40N4O8S2 | CID 6450830 - PubChem - NIH, accessed October 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/mk-0677
13. ibutamoren | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=5867
14. Ibutamoren (MK-677 free base) | GHSR Agonist - MedchemExpress.com, accessed October 22, 2025, https://www.medchemexpress.com/ibutamoren.html
15. (PDF) Structural basis of human ghrelin receptor signaling by ..., accessed October 22, 2025, https://www.researchgate.net/publication/355918323_Structural_basis_of_human_ghrelin_receptor_signaling_by_ghrelin_and_the_synthetic_agonist_ibutamoren
16. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3898933/
17. and efficacy of ghrelin in the presence of increasing concentrations of... - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/figure/and-efficacy-of-ghrelin-in-the-presence-of-increasing-concentrations-of-MK-677_tbl2_26689028
18. Growth Hormone Secretagogues and Growth Hormone Releasing Peptides Act As Orthosteric Super-Agonists but Not Allosteric Regulators for Activation of the G Protein Gαo1 by the Ghrelin Receptor - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2769045/
19. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats - PubMed Central, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6240568/
20. Ibutamoren (MK-677) HGH - Voafit, accessed October 22, 2025, https://www.voafit.com/medications/peptides/ibutamoren-hgh
21. MK-677 (Ibutamoren) side effects - Healthy Male, accessed October 22, 2025, https://healthymale.org.au/health-article/what-you-need-to-know-about-mk-677-ibutamoren
22. Beyond the androgen receptor: the role of growth hormone ..., accessed October 22, 2025, https://tau.amegroups.org/article/view/33160/28655
23. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial - PubMed Central, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/
24. Two-Month Treatment of Obese Subjects with the Oral Growth ..., accessed October 22, 2025, https://academic.oup.com/jcem/article-abstract/83/2/362/2865156
25. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/9467534/
26. (PDF) A Study of the Metabolism of Ibutamoren (MK-677), a Growth ..., accessed October 22, 2025, https://www.researchgate.net/publication/378535049_A_Study_of_the_Metabolism_of_Ibutamoren_MK-677_a_Growth_Hormone_Secretagogue_in_Human_Urine_by_Ultra-High-Performance_Liquid_Chromatography-High-Resolution_Mass_Spectrometry
27. Characterization of growth hormone secretagogue small molecule ibutamoren (MK‐0677) and its possible metabolites in thoroughbred horses for doping control | Request PDF - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/publication/361302635_Characterization_of_growth_hormone_secretagogue_small_molecule_ibutamoren_MK-0677_and_its_possible_metabolites_in_thoroughbred_horses_for_doping_control
28. MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed October 22, 2025, https://academic.oup.com/jcem/article/83/2/320/2865101
29. University of Virginia study shows new drug increases muscle mass in arms and legs of older adults | Fierce Biotech, accessed October 22, 2025, https://www.fiercebiotech.com/biotech/university-of-virginia-study-shows-new-drug-increases-muscle-mass-arms-and-legs-of-older
30. Effects of 2 months of treatment with MK-677 (25 mg) or placebo daily... - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/figure/Effects-of-2-months-of-treatment-with-MK-677-25-mg-or-placebo-daily-in-obese-males-on_tbl4_13762427
31. Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited - NIH, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8207831/
32. (PDF) Effect of Alendronate and MK-677 (a Growth Hormone ..., accessed October 22, 2025, https://www.researchgate.net/publication/12092543_Effect_of_Alendronate_and_MK-677_a_Growth_Hormone_Secretagogue_Individually_and_in_Combination_on_Markers_of_Bone_Turnover_and_Bone_Mineral_Density_in_Postmenopausal_Osteoporotic_Women
33. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/11238495/
34. Growth hormone secretagogue MK-677 | Neurology, accessed October 22, 2025, https://www.neurology.org/doi/abs/10.1212/01.wnl.0000335163.88054.e7
35. Efficacy and Safety of an Oral Growth Hormone Drug in the ..., accessed October 22, 2025, https://ctv.veeva.com/study/efficacy-and-safety-of-an-oral-growth-hormone-drug-in-the-treatment-of-fibromyalgia
36. MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed October 22, 2025, https://academic.oup.com/jcem/article-abstract/83/2/320/2865101
37. Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults 1 - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/publication/13898092_Oral_Administration_of_Growth_Hormone_GH_Releasing_Peptide-Mimetic_MK-677_Stimulates_the_GHInsulin-Like_Growth_Factor-I_Axis_in_Selected_GH-Deficient_Adults_1
38. Performance Enhancing Substance: MK-677 (Ibutamoren) - Operation Supplement Safety, accessed October 22, 2025, https://www.opss.org/article/performance-enhancing-substance-mk-677-ibutamoren
39. Phase 2 Trial Evaluating LUM-201 for Treatment of Growth Hormone Deficiency, accessed October 22, 2025, https://checkrare.com/phase-2-trial-evaluating-lum-201-for-treatment-of-growth-hormone-deficiency/
40. Phase 2 Trial Evaluating LUM-201 for Treatment of Growth Hormone Deficiency - YouTube, accessed October 22, 2025, https://www.youtube.com/watch?v=BWI7TSw_Xvk
41. Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults* | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed October 22, 2025, https://academic.oup.com/jcem/article/82/10/3455/2823475
42. FIG. 3. Body composition during 2-month treatment with MK-677 (25 mg)... - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/figure/Body-composition-during-2-month-treatment-with-MK-677-25-mg-or-placebo-daily-in-obese_fig1_13762427
43. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial: Annals of Internal Medicine - ACP Journals, accessed October 22, 2025, https://www.acpjournals.org/doi/10.7326/0003-4819-149-9-200811040-00003
44. MP85-02 IMPACT OF GROWTH HORMONE SECRETAGOGUES ..., accessed October 22, 2025, https://www.auajournals.org/doi/10.1016/j.juro.2018.02.2862
45. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/9661080/
46. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women - Northwestern Scholars, accessed October 22, 2025, https://www.scholars.northwestern.edu/en/publications/effect-of-alendronate-and-mk-677-a-growth-hormone-secretagogue-in
47. Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women1 | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed October 22, 2025, https://academic.oup.com/jcem/article-abstract/86/3/1116/2847590
48. Ibutamoren Completed Phase 2 Trials for Fibromyalgia Treatment | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/drugs/DB18214/clinical_trials?conditions=DBCOND0002221&phase=2&purpose=treatment&status=completed
49. Does Ibutamoren (MK-677) Really Help You Sleep Better? - ClinicSpots, accessed October 22, 2025, https://www.clinicspots.com/blog/does-ibutamoren-mk-677-really-help-you-sleep-better
50. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man - ProQuest, accessed October 22, 2025, https://search.proquest.com/openview/9bbca2d4c082addc2bd1678958abc9f1/1?pq-origsite=gscholar&cbl=41201
51. Prolonged oral treatment with MK-677, a novel growth hormone ..., accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/9349662/
52. Best Ibutamoren Beverly Hills & Newport Beach | AsandraMD Anti-Aging, accessed October 22, 2025, https://asandramd.com/anti-aging-beverly-hills/growth-hormone-treatments/ibutamoren/
53. Ibutamoren (MK 677) Not OK - Don't Be Fooled By Marketing! - Sport Integrity Australia, accessed October 22, 2025, https://www.sportintegrity.gov.au/news/integrity-blog/2022-05/ibutamoren-mk-677-not-ok-dont-be-fooled-marketing
54. Beyond the Hype: Potential Health Risks of MK-677 | Get Smart About Drugs, accessed October 22, 2025, https://www.getsmartaboutdrugs.gov/news-statistics/2025/07/08/beyond-hype-potential-health-risks-mk-677
55. Beyond the Hype: Potential Health Risks of MK-677 | Just Think Twice, accessed October 22, 2025, https://www.justthinktwice.gov/news-statistics/2025/07/08/beyond-hype-potential-health-risks-mk-677
56. LGD-4033 and MK-677 use impacts body composition, circulating ..., accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/36303408/
57. Hepatotoxicity induced by MK-677 - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/40675653/
58. 1.4. Ibutamoren | Therapeutic Goods Administration (TGA), accessed October 22, 2025, https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-november-2017/14-ibutamoren
59. Search Orphan Drug Designations and Approvals - FDA, accessed October 22, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=579617
60. Elite Supplement Center LLC and Elite Training Facility LLC - 627498 - 07/06/2022 | FDA, accessed October 22, 2025, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/elite-supplement-center-llc-and-elite-training-facility-llc-627498-07062022
61. Screen Your Dietary Supplements | U.S. Anti-Doping Agency - USADA, accessed October 22, 2025, https://www.usada.org/dietary-supplements/screen-dietary-supplements/
62. The Prohibited List | World Anti Doping Agency - WADA, accessed October 22, 2025, https://www.wada-ama.org/en/prohibited-list
63. Hgh vs sermorelin | hgh peptide therapy near me - Kenton Bruice, MD, accessed October 22, 2025, https://kentonbruicemd.com/hgh-therapy-and-sermorelin-what-is-the-difference/
64. Human growth hormone (HGH): Does it slow aging? - Mayo Clinic, accessed October 22, 2025, https://www.mayoclinic.org/healthy-lifestyle/healthy-aging/in-depth/growth-hormone/art-20045735